Ann: Bupa UK Approves Reimbursement for OncoSil in the UK, page-30

At the moment its limited to cancer of the pancreas which is a much smaller patient population than the primary or secondary liver cancer that Sirtex treats.

If, however, Oncosil can be injected into the same liver lesions that Sirtex treats, it would expand the market greatly.

Similarly, if it can be injected safely and effectively into kidney cancers, it grows the market.

Breasts? Maybe

But there are no studies on those organs yet.

Essentially, I see Oncosil as a substitute for external radiation. Much more targetted, much fewer side effects on surrounding tissue.

I see Sirtex as a natural acquirer of the company and the technology. It complements Sirtex's current technology and gives it a wider suite of injected radiopharmaceuticals. Also Sirtex has been working out the registration issues in the various markets, so Oncosil gets a free ride on that work done with the regulators. Also Sirtex has an established team of sales representatives. Also, most of current Oncosil team worked for Sirtex at senior levels, so are trusted. Doesn;t take much imagination.......

If for no other reason, that makes the current market cap a complete joke.